Regulators in Spain are punishing a Barcelona-based drugmaker for a series of manufacturing shortfalls, recalling all batches produced by the company, Farma Mediterrania, from 2014 to present. The crackdown is the second in as many months by Spanish authorities on local producers.
Capsulemaker Qualicaps is adding another country, and another continent, to its manufacturing network. It has secured a spot in Brazil with the acquisition of a capsulemaker there.
Catalent's plant in Beinheim, France, offline for four months because of suspected sabotage to products, is expected to be fully up and running next month. It is a good thing for the Somerset, NJ-based company since its suspension of the soft-gel capsule plant shaved $21 million off its top line in the last quarter and led it to lower its forecast for the year.
Some drugmakers are expanding production in Africa to take advantage of a growing number of countries where rising incomes and national healthcare can pay for new meds. Now, through a number of sources of financing, a new plant will be built to manufacture yellow fever vaccine, a protection that has been in short supply.
India's Strides Shasun has been expanding and will add a seventh manufacturing site to its operations in Africa after buying controlling interest in a Kenyan drug producer.
Sanofi is looking to trim 600 jobs in France as part of new CEO Olivier Brandicourt's plan to squeeze €1.5 billion in annual costs. The drugmaker says it does not plan on closing any plants in France as part of the process, but that does not mean that its production network in the home country will escape unscathed. Brandicourt has also said he will "reshape" the manufacturing network as part of his overall reorganization of the company.
Piramal Enterprises, with a big dose of incentives, snapped up Coldstream Laboratories last year from the University of Kentucky to get its expertise in sterile injectable meds. Now it has plans on investing another sizable chunk to expand the CDMO.
Years ago, German CDMO Vetter determined that in addition to building out its manufacturing capacity, it needed to expand its IT infrastructure to continue to satisfy clients. Now after two years, Vetter has wrapped up work on a 91,500-square-foot multipurpose facility in Schuetzenstrasse, Germany, that bulks up computing operations.
Allergan is putting finishing touches on a $50 million expansion of its flagship plant in Waco, TX, but CEO Brent Saunders says the drugmaker may be looking to the facility for more capacity and add jobs as result.
Since Eli Lilly closed its $5.4 billion deal last year to buy Novartis Animal Health, Lilly has been doing an in-depth evaluation of its global manufacturing operations. The conclusions it has reached are bad news for more than 100 workers at plants in Ireland and Scotland.